PMC

Competitive inhibition of CaM binding to SR vesicles by S100A1. SRs from skeletal (A) or cardiac (B) muscle were preincubated with WT-S100A1 or WT-CaM with 30 nm (blue solid symbol) or 300 μm (red open symbol) Ca²⁺ and then incubated with 0.1 μm A-CaM before SR membrane sedimentation by centrifugation. Data are normalized to no-S100A1 or no-CaM controls (black dotted lines) and expressed as means ± S.E. (n = 4). *, significantly different from control, p < 0.05 as determined by paired Student's t test.

Hypothesis tested and RyR-targeted FRET molecular toolkit. S100A1 (orange) competes with CaM (green) binding to RyR (light blue). The RyR1 model (cyan) is based on a published cryo-EM density map (Protein Data Bank code 3J8H) () with docked FKBP12 (dark blue) and suggested location of the CaM binding site () indicated (shaded oval). FKBP and CaM N-lobe bind to locations that are within ∼50 Å from each other in the RyR complex, a feature that is exploited by our FRET-based system to investigate the RyR structure and binding events in vitro and in situ ().

Competitive inhibition of A-CaM binding to RyR1 and RyR2 by S100A1. RyR in native SR membranes isolated from skeletal or cardiac muscle was labeled with D-FKBP, preincubated with S100A1 (0–400 μm), and then incubated with 0.1 μm A-CaM (labeled via T34C mutation). The inhibition of CaM bound to RyR was calculated as the fractional decrease of FRET between D-FKBP and A-CaM, based on the fluorescence intensity readout. Shown are representative fluorescence spectra of samples preincubated with unlabeled CaM (A) or S100A1 (B). Such measurements are plotted as competition curves for samples consisting of skeletal (C) and cardiac (D) SR. Data are shown as mean FRET ± S.E. (n = 4). *, significantly different from no-S100A1 controls, as determined by paired Student's t test.

CaM alters the effect of S100A1 on [³H]ryanodine binding to RyR1 and RyR2. SR vesicles from skeletal or cardiac muscle were incubated with S100A1 (0–100 μm) and CaM (0 or 800 nm) at 30 nm or 30 μm Ca²⁺ in the presence of [³H]ryanodine. A, as a control, the functional effect of 800 nm CaM was tested on [³H]ryanodine binding to skeletal (left) and cardiac (right) SR vesicles in 30 nm (blue) or 30 μm (red) Ca²⁺. Data are shown as individual data points (square) and mean ± S.E. (open circle). The fraction of [³H]ryanodine binding is relative to “no CaM” control. B, effect of S100A1 on [³H]ryanodine binding to skeletal SR (top panels) and cardiac SR (bottom panels) at 30 nm Ca²⁺ (left) and 30 μm Ca²⁺ (right) and in the absence of CaM (hollow squares) and in the presence of 800 nm CaM (solid squares). Control levels (absence of S100A1) are indicated by dashed lines. The fraction of [³H]ryanodine bound to SR vesicles is relative to maximum binding capacity (B_max). Data are shown as mean ± S.E. (n = 6–8). *, significant differences relative to no-S100A1 controls; p < 0.05, as determined by paired Student's t test.

Competition of A-S100A1 by unlabeled S100A1 and CaM for binding to RyR. RyRs in SR membranes isolated from skeletal or cardiac muscle were labeled with D-FKBP and incubated with A-S100A1. Binding specificity of A-S100A1 to RyR was investigated by the addition of a >10-fold molar excess of unlabeled S100A1 or CaM. Saturation binding of AF568-S100A1-C85S-ACA to RyR from skeletal (A) and cardiac (B) SR is indicated as Total (solid lines) at 30 nm Ca²⁺ (blue) and 30 μm Ca²⁺ (red). Total FRET is compared with the saturation binding curve in the presence of 40 μm WT-S100A1 (dotted lines) or 40 μm WT-CaM (dashed lines). Binding specificities of several A-S100A1 variants to RyR from skeletal SR (C) or cardiac SR (D) were tested by the addition of 20 μm CaM (blue circles), WT-S100A1 (pink circles), or unlabeled S100A1 (green circles). Data are expressed as means ± S.E. (n = 4). *, significantly different from respective control (black circles), p < 0.05, as determined by analysis of variance with Fisher's post hoc test.

TR-FRET detection of S100A1 structural effect on the CaM·RyR complex. SR membranes from skeletal (A, C, and E) or cardiac (B, D, and F) muscle were labeled with D-FKBP, preincubated with 200 μm S100A1, and then incubated with 800 nm CaM labeled with acceptor probe at the N-lobe residue via T34C (A_N-CaM). A and B, fluorescence decays of D-FKBP with A_N-CaM in low (blue) and high Ca²⁺ (red), with (dotted lines) and without (solid lines) S100A1. C and D, multiexponential analysis of the TR-FRET data yielded a two-distance (R₁ and R₂) Gaussian distribution model of the separation between D-FKBP and A_N-CaM within RyR. E and F, molar fractions of the populations associated with each of the two structural states characterized by distances R₁ and R₂. The S100A1 effects are shown in hatched bars. *, significantly different from the no-S100A1 control. #, significantly different from 30 nm Ca²⁺, p < 0.05, as determined by analysis of variance with Fisher's post hoc test.